CHGA and neoplasm: Though different circulating biomarkers (chromogranin A and B, pancreastatin, neuron-specific enolase, pancreatic polypeptide) have been analyzed in NENs, they lack adequate accuracy or metrics to be considered in routine clinical practice as NET screening or monitoring markers, apart from specific hormones released in selected functioning tumours [28].